Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
33,353
Total Claims
$4.1M
Drug Cost
1,123
Beneficiaries
$3,612
Cost/Patient
Risk Score Breakdown 3/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+156%
Cost per patient vs peers
$3,612 vs $1,411 avg
+63%
Brand preference vs peers
17.3% vs 10.6% avg
Brand vs Generic
Brand: 5,675 claims · $3.4M
Generic: 27,132 claims · $602K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Icosapent Ethyl | 1,235 | $536K |
| Empagliflozin | 537 | $408K |
| Tenofovir Alafenamide | 221 | $347K |
| Denosumab | 119 | $206K |
| Sitagliptin Phosphate | 254 | $189K |
| Sitagliptin Phos/Metformin Hcl | 239 | $164K |
| Apixaban | 225 | $160K |
| Icosapent Ethyl | 453 | $137K |
| Dapagliflozin Propanediol | 152 | $119K |
| Semaglutide | 110 | $117K |
| Rivaroxaban | 147 | $107K |
| Linaclotide | 175 | $103K |
| Diclofenac Epolamine | 146 | $97K |
| Dulaglutide | 58 | $67K |
| Romosozumab-Aqqg | 26 | $65K |
Prescribing Profile
Patient Profile
72
Avg Age
49%
Female
1.14
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data